In this Decade in Review article, I highlight the top 10 advances in heart failure (HF) over the past decade, including new pharmacological therapies and expanded indications for devices in HF with reduced ejection fraction. The poor progress in acute HF and HF with preserved ejection fraction is emphasised. Biomarkers and devices that help prevent, detect, and guide treatment represent the future of HF management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart failure events. N . Engl. J. Med. 361, 1329–1338 (2009).
McMurray, J. J. et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart. Fail. 16, 817–825 (2014).
Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875–885 (2010).
Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011).
Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383–1392 (2014).
Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436–2448 (2009).
Teerlink, J. R. et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. L ancet 381, 29–39 (2013).
Jessup, M. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304–313 (2011).
Ledwidge, M. et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310, 66–74 (2013).
Troughton, R. W. et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur. Heart. J. 35, 1559–1567 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.K. declares that he has received research grants from Bayer, Medtronic, Novartis, Pfizer, and Servier.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Krum, H. 10 Years of progress in HF research—what have we learned?. Nat Rev Cardiol 11, 631–633 (2014). https://doi.org/10.1038/nrcardio.2014.127
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.127
